Review article: induction therapy for patients with active ulcerative colitis
|
|
- Sharleen Barber
- 5 years ago
- Views:
Transcription
1 Alimentary Pharmacology & Therapeutics Review article: induction therapy for patients with active ulcerative colitis S. P. L. TRAVIS John Radcliffe Hospital and Linacre College, Oxford, UK Correspondence to: Dr S. P. L. Travis, John Radcliffe Hospital, Oxford OX3 9DU, UK. Publication data Accepted 28 June 2006 SUMMARY 5-aminosalicylic acid (mesalazine) is considered first-line therapy for active mild moderate, left-sided or extensive ulcerative colitis. With modern delayed-release formulations, conventional doses are very well tolerated, and there is accumulating evidence that increasing the dose, to >4 g/day, leads to higher response rates and earlier symptom relief in patients with ulcerative colitis. There is evidence that combining oral and rectal (enema) formulations of 5-aminosalicylic acid leads to faster and higher remission rates. Despite the fact that clinical trials in ulcerative colitis have often used different endpoints, making it difficult to make objective comparisons, the evidence now strongly suggests that it is appropriate to start patients with mild or moderately active ulcerative colitis on doses of 5- aminosalicylic acid of at least 4 g/day. For those with extensive disease, adding rectal 5-aminosalicylic acid improves remission rates; the same seems likely to be true for limited disease, but robust evidence is lacking. Rectal 5-aminosalicylic acid may in fact be sufficient on its own for patients with active proctitis. Patients with mild moderate ulcerative colitis who do not improve within 2 weeks of high-dose 5-aminosalicylic acid should have treatment augmented by oral steroids. Aliment Pharmacol Ther 24 (Suppl. 1), ª 2006 The Author
2 REVIEW: INDUCTION THERAPY FOR PATIENTS WITH UC 11 INTRODUCTION The British Society of Gastroenterology (BSG) guidelines recommend 5-aminosalicylic acid (5-ASA) as first-line therapy for active mild moderate, left-sided or extensive ulcerative colitis (UC), unless a prompt response is required that necessitates steroids. 1 Increasing the dose of sulfasalazine to increase its therapeutic effect, however, was found to be limited by side-effects. The advent in 1987 of mesalazine (5-ASA) with its superior side-effect profile allowed higher dosing, showing that increasing the dose could give further benefit. 2 Remission rates achieved in this early study were low, 2 possibly because stringent definitions of complete remission were used with stool frequency, rectal bleeding, flexible proctosigmoidoscopy findings and Physician s Global Assessment (PGA) all scoring zero. The overall response rate (complete and partial response) improved from 27% in patients taking 1.6 g/day to 74% in patients taking 4.8 g/day compared with an overall response rate of 18% in patients taking placebo. Similarly, the remission rate improved from 9% to 24% compared with 5%, respectively. 2 In a subsequent trial of 374 patients with mild moderate active UC, 2 and 4 g/day of 5-ASA were superior to placebo, 3 in terms of both remission and response. There appeared, however, to be a plateau for remission at 29% for both 2 and 4 g/day compared with placebo at 12%. Nevertheless, 4 g/day produced greater improvement in clinical symptoms, greater endoscopic improvement and greater histological improvement than 2 g/day (Figure 1). The study also showed that the efficacy of 5-ASA was independent of the extent of disease or recent steroid use. Adverse effects were independent of dose and, intriguingly, were less frequent in patients in the active-treatment groups than in those in the placebo group. This study demonstrated that dose escalation of 5-ASA without toxicity was possible. A Cochrane meta-analysis has confirmed that 5-ASA is twice as effective as placebo for inducing remission (Figure 2). 4 A systematic review has also examined all nine published placebo-controlled clinical trials of 5-ASA up to The remission rate in patients treated with 5-ASA was indeed twice that in patients given placebo approximately 20% vs. 10%, respectively, at 6 12 weeks and dose-dependent, but the authors identified only a modest improvement in remission as the dose of 5-ASA was increased. They therefore concluded that 5-ASA alone was not % of patients Remission Success Benefit ASA (g/day) Figure 1. Effect of dose of 5-aminosalicylic acid (5-ASA) on remission, success and perceived benefit in patients with active mild moderate ulcerative colitis. Reproduced from Hanauer et al. (1993), 3 with permission. particularly effective in inducing remission; the number needed to treat (NNT) to produce one remission was 10, compared with only two for corticosteroids. 5 The questions that remain are whether dose escalation was sufficient and whether the clinical heterogeneity of mixing mild and moderately active disease, let alone patients with different disease distributions, obscured the benefit. One of the complications of comparing clinical trials is that different study groups have used different definitions of disease severity. There are at least eight ways to define disease severity. 6 There is, as yet, no internationally agreed standard classification of severity of disease and, even more remarkably, no standard definition of remission. If mild and moderately active disease severities are going to be differentiated, then the two strata should mean that there are differences in management or outcome; otherwise clinicians need only discriminate between severe UC and less active disease. This is particularly pertinent now that there are several new trials of 5-ASA compounds and up to 30 new agents in Phase I III trials for inflammatory bowel disease (IBD). 7 Moderately active disease can also be defined by sigmoidoscopy score, with the presence of mucosal friability discriminating moderate
3 12 S. P. L. TRAVIS Figure 2. Results of a Cochrane database meta-analysis of the ability of 5-aminosalicylic acid (5-ASA) to induce remission in patients with mild moderate active ulcerative colitis. Reprinted from Sutherland and MacDonald (2003), 4 with permission. from mild inflammation. Because neither the clinical nor the endoscopic score have been validated in the era of flexible sigmoidoscopy and because interobserver variation is undefined, it can be seen that the definitions are less than precise. This is very likely to have an impact on outcome. EFFECTS OF INCREASING THE DOSE Asacol The most recent well-designed large studies of the effect of 5-ASA were the two Assessing the Safety and Clinical Efficacy of a New Dose (ASCEND) studies (ASCEND of 5-ASA). 8, 9 The objective of these two studies was to evaluate the safety and efficacy of 4.8 g/day of 5-ASA (using a novel high-dose formulation with 800 mg tablets) in comparison with 5-ASA 2.4 g/day (using the conventional 400 mg tablets) for active UC over a 6-week period. The ASCEND studies assessed disease severity with the PGA where 1 is mild and 2 is moderate. The Mayo score was used to evaluate response; this is a composite index measuring rectal bleeding, stool frequency, PGA and sigmoidoscopy, with mild scoring 2 4 and moderate The two studies were double-blind, randomized, multi-site, active control studies in patients with active UC. The ASCEND studies were initially designed to evaluate patients with mild moderate active UC. Once complete, ASCEND I showed that patients with moderately active disease received significant benefit from 4.8 g/day but those with mild disease did not. Thus, the ASCEND II protocol was amended during the study, prior to unblinding, to evaluate efficacy in moderate-uc patients. The primary endpoint was the percentage of patients classified as having an overall improvement ( treatment success ) at the end of 6 weeks. Complete remission was recorded as having been achieved if all clinical assessments and the PGA score were zero. A response was deemed to be an improvement from baseline in PGA and improvement from baseline of at least one clinical assessment, providing that there was no worsening in any clinical assessment. Clinical assessments included stool frequency, rectal bleeding, patient functional assessment and sigmoidoscopy. Overall improvement was defined as the combination of remission and response. The ASCEND I study, which assessed 301 patients, showed only a significant benefit for patients with moderately active disease; 57% of patients treated with 2.4 g/day achieved overall improvement compared with 72% on 4.8 g/day (P ¼ ). 8 This was independently confirmed in the ASCEND II study of identical design. 9 At 6 weeks, patients given the higher dose faired significantly better overall improvement was 59% for the 2.4 g/day dose vs. 72% for the 4.8 g/day dose (P ¼ 0.036; Figure 3). 9 There was, however, no clinically relevant increase in remission rates between 2.4 and 4.8 g/day at 6 weeks (from 18% to 20%).
4 REVIEW: INDUCTION THERAPY FOR PATIENTS WITH UC 13 % of patients * n = 130 n = g/day 4.8 g/day *P < 0.05 Table 1. Safety and tolerability data from ASCEND II [data from Hanauer et al. (2005). 9 ] 2.4 g/day [n ¼ 139; n (%)] 4.8 g/day [n ¼ 129; n (%)] Patients with AEs 49 (35) 57 (44) Patients with serious AEs 2 (1.4) 1 (0.8) Patients withdrawn due to AEs 4 (2.8) 4 (3.1) Figure 3. Overall improvement at week 6, Assessing the Safety and Clinical Efficacy of a New Dose (ASCEND) II study programme. Reproduced from Hanauer et al. (2005), 9 with permission. ASCEND, Assessing the Safety and Clinical Efficacy of a New Dose; AE, adverse effect. One of the problems with the disease activity score used (PGA) is that it includes the subjective variables of doctor and patient perception of benefit. These are of course important impressions, but they lack the objectivity of measurable variables. The objective variables in this index are stool frequency and rectal bleeding, both of which are symptoms of active disease that matter to patients. In ASCEND II, doubling the dose of 5-ASA to 4.8 g/day shortened the time to resolution of increased stool frequency, rectal bleeding and a combination of the two. In the population of patients with moderate disease, increasing the dose from 2.4 to 4.8 g/day led to trends towards reduction in the median time to normalization of stool frequency from 13 days to 10 days (P ¼ 0.288), and of the combined endpoint of stool frequency and rectal bleeding from 32 days to 21 days (P ¼ ). However, the reduction in the time to cessation of rectal bleeding was significant from 16 days to 9 days (P ¼ 0.035). Consequently, the results of ASCEND I and II provide good evidence that doubling the dose of 5-ASA from the conventional 2.4 g/day produces moderate, but worthwhile, benefits to patients with active UC. In ASCEND II, the absolute benefit was 13% at 6 weeks in patients taking 4.8 g/day (P ¼ 0.036), while the median time to cessation of rectal bleeding was nearly halved (from 16 days for the lower dose to 9 days for the higher dose). This was achieved without any clinically relevant increase in adverse effects (Table 1), despite the fact that doubling the dose also doubled the serum concentration of 5-ASA and N-acetyl-5- ASA. Furthermore, the tablet burden will decrease once 800 mg Asacol (Egham, Surrey, UK) tablets become available, i.e mg tablets per day compared with mg tablets per day. SPD 476 SPD 476 is a multimatrix formulation of 5-ASA that includes a ph-sensitive coat around a matrix of hydrophilic polymer containing a portion of 5-ASA, together with lipophilic excipients that encapsulate additional 5-ASA. The lipophilic particles are reported to have the ability to stick to membranes, which is intended to create high concentrations of released 5-ASA near the colonic epithelium. The formulation has been evaluated in patients with mild moderate UC and is still under investigation and subject to approval. 10 Patients with mild moderate UC (n ¼ 280) were randomized to receive either SPD g twice daily or SPD g once daily or placebo for 8 weeks. The primary endpoint was remission at the end of the 8 weeks. Remission was defined as a UC disease activity index (DAI) score 1, with a score of zero for stool frequency and rectal bleeding, together with a reduction of at least one point in the sigmoidoscopy score. 10 Once and twice daily dosing produced similar results. Remission rates were 29% and 34%, respectively (4.8 g/day once daily vs. 2.4 g/day twice daily), compared with 13% on placebo (P < 0.01; Figure 4). These are within the range expected in trials of oral 5-ASA, although higher than the mean. 2, 3, 5 Clinical improvement rates of 60% (4.8 g once daily) and 56% (2.4 g twice daily), compared with 26% on placebo, were comparable with those observed in other highdose 5-ASA trials. The most interesting aspect is the efficacy of the once daily dosing. While this is unli-
5 14 S. P. L. TRAVIS % of patients Placebo SPD g bd kely to have a major impact on the treatment of active disease, it is likely to find favour for maintenance if subsequent trials confirm a benefit in remission. In general, the once daily regimen was well tolerated, although two cases of pancreatitis occurred in the 280 patients; both cases were receiving SPD 476 rather than placebo. Any differences in efficacy or adverse events in this trial (compared with other 5-ASA trials) may reflect differences in methodology. The endpoint of remission was tightly defined, but there was no independent histology. The impact of any differences would be expected to disappear in the randomization process, but the trial population included patients from centres from a range of countries not widely used in other UC trials, and for which no historical remission rates with other formulations of 5-ASA are available. The population in the study also included a higher proportion with mild disease and 12% had no rectal bleeding at entry. Nevertheless, the study clearly shows that once daily dosing with 5-ASA is effective, hence there is a need to re-examine the requirement for multiple dosing regimens. Combined oral and rectal 5-ASA SPD g od Remission Response Figure 4. Comparison of multimatrix 5-aminosalicylic acid (5-ASA) 2.4 g twice daily with 4.8 g once daily (bd) in patients with mild moderate ulcerative colitis (od). Data from Lichtenstein et al. (2005). 10 High doses of the slow-release rectal formulation of 5-ASA, Pentasa (Lucerne, Switzerland), have also been assessed in a clinical trial in patients with extensive, mild moderate active UC. 11 Patients (n ¼ 127) were randomized to receive either Pentasa 4 g/day (twice daily dosing) oral mesalazine for 8 weeks plus 1 g/day Pentasa enema, or 4 g/day plus a placebo enema. At 4 weeks, 89% of the patients given both the oral dose and enema had improved, compared with 62% in the placebo enema group (P ¼ ). The remission rate was also greater in the active-enema group 64% compared with 43% in the placebo-enema group (P ¼ 0.03) at 8 weeks. These rates are extremely high and among the highest for any trial of mesalazine. Remission was defined as a DAI <2, so traces of blood or double the normal stool frequency were technically acceptable as remission if the sigmoidoscopy was normal. The main value of this study is that other trials involving enemas have traditionally excluded patients with extensive disease. It clearly demonstrates the added value of rectal 5-ASA when treating patients with extensive UC, and this applies to distal disease as well. 12 IMPACT OF THE DEFINITION OF REMISSION In UC, there are at least three definitions of remission, which may be termed clinical, regulatory or complete remission. Clinical remission is what is used in practice, meaning cessation of rectal bleeding and normal stool frequency. This is not the same as regulatory remission (the one currently, but not exclusively, favoured by the FDA), which means cessation of rectal bleeding and a sigmoidoscopy score of 0 or 1 (normal appearance, or erythema only). This in turn is not the same as complete remission, where there is normal stool frequency, no rectal bleeding and normal or quiescent appearances of the mucosa at sigmoidoscopy. The potential impact of these three definitions is considerable, but many trials simply use an arbitrary threshold (0, 1 or 2) of one of the disease activity indices, or <150 in the complex Seo index, to define the remission endpoint. 6 Obscured in these definitions can be symptoms (such as bleeding or increased stool frequency) that clinicians and their patients would not recognize as remission (Table 2). In a pooled analysis of the ASCEND studies, which included a total of 687 patients with mild moderate active UC, the remission rate can vary from 22% [complete remission (score ¼ 0) of stool frequency, rectal bleeding, sigmoidoscopy findings, patient functional assessment and PGA] to 28% (DAI 1 with no bleeding and normal frequency and at least a 1-point
6 REVIEW: INDUCTION THERAPY FOR PATIENTS WITH UC 15 Table 2. Outcome criteria for remission Clinical remission decrease in sigmoidoscopy score), and 50% (DAI 2, with no individual subscore >1). 13 When the interobserver variation in sigmoidoscopy score is factored in (and Baron et al. originally based their score on >60% agreement 14 ) the rates of remission defined in trials are open to considerable differences in interpretation. This is a crucial issue for regulatory authorities, since the currently favoured definition depends substantially on sigmoidoscopy. In the future, trials should have independent evaluation of sigmoidoscopy using video imaging, together with a histological record of disease activity. This is because a normal, pre-treatment rectal biopsy excludes a diagnosis of active UC, even though there is no clear correlation between clinical, endoscopic and histological disease activity. This means that any patient with a normal, pre-treatment biopsy should be excluded from the trial and many patients with mild disease might well have symptoms provoked by an irritable bowel as much as by active colitis. RAPIDITY OF RESPONSE Regulatory remission Rectal bleeding score Stool frequency score 0 0 Sigmoidoscopy score 0/1 0/1 Complete remission Speed of response is an often-neglected aspect of treatment, despite its importance to patients. The number of days to relief of objective symptoms (increased stool frequency, rectal bleeding) is a useful measure that is easier to interpret than reductions in scores of disease activity indices. These data should be provided in reports on clinical trials and include the breakdown of the disease activity indices with numbers of actual patients. Otherwise it can be impossible to determine whether an improvement in the index has been driven by the subjective PGA, the patient s functional assessment or an objective measure of symptoms. In the ASCEND II study the median time to cessation of rectal bleeding was just 9 days in those receiving 4.8 g/day. 9 In a study of combined oral and enema treatment with Pentasa in patients with extensive mild moderate active UC, which had a much higher apparent remission rate, the time to cessation of rectal bleeding in 50% of those with frank bleeding at entry was 21 days in the combined oral and enema group. 11 In addition, among patients with any rectal bleeding at baseline, bleeding had ceased within 56 days of treatment in 73% of mesalazine enema-treated patients compared with 38% of placebo enema-treated patients. 11 Analyses of stool frequency data were not reported in this study. An important message for clinical practice is that there is no need to wait the 6 8 weeks duration of clinical trials to determine the response to high-dose 5-ASA induction therapy. Patients who do not improve within 2 weeks should be considered for decisive treatment with steroids. CONCLUSIONS High-dose (>4 g) 5-ASA is appropriate as initial treatment for patients with mild or moderately active UC. Adding rectal therapy with 5-ASA (i.e. as an enema) has added benefits compared with oral 5-ASA alone even in those patients with extensive disease, although rectal 5-ASA alone may be sufficient for some patients with active proctitis. Patients with mild moderate UC who do not improve within 2 weeks of high-dose 5- ASA should have treatment augmented by oral steroids. REFERENCES 1 Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004; 53 (Suppl. 5): V Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317: Hanauer S, Schwartz J, Robinson M, et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am J Gastroenterol 1993; 88: Sutherland L, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2003; 3: CD Bebb JR, Scott BB. How effective are the usual treatments for ulcerative colitis? Aliment Pharmacol Ther 2004; 20: Irvine EJ. Assessing outcomes in clinical trials. In: Satsangi J, Sutherland L, eds. Inflammatory Bowel Diseases. London: Churchill Livingstone, 2003:
7 16 S. P. L. TRAVIS 7 Travis SPL, Hanauer SB, Richter J. Advances in therapeutic approaches to ulcerative colitis and Crohn s disease. Curr Gastroenterol Rep 2005; 7: Hanauer SB, Sandborn WJ, Archambault A, Dallaire C, Yacyshyn B, Regalli G. Efficacy and safety of Asacol 4.8 g/day (800 mg tablet) compared with 2.4 g/ day (400 mg tablet) in treating moderately active ulcerative colitis. Can J Gastroenterol 2006; 20 (Suppl. A): A Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol 2005; 100: Lichtenstein G, Kamm M, Sandborn W, Boddu P, Gubergrits N. SPD476, a novel once-daily, high dose mesalazine formulation is well tolerated and effective for the induction of remission of mildto moderate ulcerative colitis: a Phase III study [abstract]. Gut 2005; 54 (Suppl. VII): A Marteau P, Probert CS, Lindgren S, et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 2005; 54: Safdi M, DeMicco M, Sninsky C, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 1997; 92: Katz S, Kane S, Higgins P, Yacyshyn B, Eusebio R. Different definitions of remission for ulcerative colitis result in large variations of clinical outcome scores [DDW abstract]. Gastroenterology 2006; 130 (suppl. 2): A (Abstract). 14 Baron JH, Connell AM, Lennard-Jones J. Variation between observers in describing mucosal appearances in proctocolitis. BMJ 1964; 5375:
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 20 October 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 20 October 2010 MEZAVANT LP 1200 mg, prolonged-release gastro-resistant tablets B/60 (CIP code: 378 689-2) Applicant
More informationOnce Daily Dosing for Induction and Maintenance of Remission in Ulcerative Colitis
Once Daily Dosing for Induction and Maintenance of Remission in Ulcerative Colitis John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University JKM 2014 Svartz N. Acta Med Scand
More informationMonth/Year of Review: September 2012 Date of Last Review: September 2010
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationMild-moderate Ulcerative Colitis Sequential & Combined treatments need to be tested. Philippe Marteau, Paris, France
Mild-moderate Ulcerative Colitis Sequential & Combined treatments need to be tested Philippe Marteau, Paris, France Sequential vs combined treatments When should one switch? Sequential vs combined treatments
More informationAs clinicians we would all agree that the goal for our
CURRENT CONTROVERSIES: PRO, CON, AND BALANCE Controversies in Mucosal Healing in Ulcerative Colitis Sunanda Kane, MD,* Frances Lu, MD, Asher Kornbluth, MD, Dahlia Awais, MD, and Peter D.R. Higgins, MD,
More informationUlcerative colitis (UC) is a chronic disease that is commonly
ORIGINAL ARTICLE Voting with Their Feet (VWF) Endpoint: A Meta-Analysis of an Alternative Endpoint in Clinical Trials, Using 5-ASA Induction Studies in Ulcerative Colitis Sujal C. Rangwalla, DO,* Akbar
More information5-aminosalicylic acid (5-ASA) is the mainstay of first-line therapy
MMX Mesalamine for Induction and Maintenance Therapy in Mild-to-Moderate Ulcerative Colitis Stephen B. Hanauer, MD 1 ; Gary R. Lichtenstein, MD 2 ; Michael A. Kamm, MD 3 ; William J. Sandborn, MD 4 ; Kirstin
More informationHow to Optimize Induction and Maintenance Responses: Definitions and Dosing Advances in Inflammatory Bowel Disease December 6, 2009
How to Optimize Induction and Maintenance Responses: Definitions and Dosing 2009 Advances in Inflammatory Bowel Disease December 6, 2009 Fernando Velayos MD MPH University of California, San Francisco
More informationRandomised clinical trial: delayed-release oral mesalazine 4.8 g day vs. 2.4 g day in endoscopic mucosal healing ASCEND I and II combined analysis
Alimentary Pharmacology and Therapeutics Randomised clinical trial: delayed-release oral mesalazine 4.8 g day vs. 2.4 g day in endoscopic mucosal healing ASCEND I and II combined analysis G. R. Lichtenstein*,
More informationLiterature Review: CORE I & II: COlonic RElease Budesonide for the Induction of Remission for Mild- Moderate Ulcerative Colitis
VOLUME 13, ISSUE 1, YEAR 2014 Literature Review: CORE I & II: COlonic RElease Budesonide for the Induction of Remission for Mild- Moderate Ulcerative Colitis Peter R. McNally, DO, MACG, MSRF Center for
More informationOral mesalamine formulations are first-line treatments
COCHRANE REVIEW Once Daily Oral Mesalamine Compared to Conventional Dosing for Induction and Maintenance of Remission in Ulcerative Colitis: A Systematic Review and Meta-Analysis Brian G. Feagan, MD, and
More information5-ASA Therapy, Steroids and Antibiotics in Inflammatory Bowel Disease
5-ASA Therapy, Steroids and Antibiotics in Inflammatory Bowel Disease David T. Rubin, MD Associate Professor of Medicine Co-Director, Inflammatory Bowel Disease Center University it of Chicago Medical
More informationTreatment Goals. Current Therapeutic Pyramids Crohn s Disease Ulcerative Colitis 11/14/10
Current Management of IBD: From Conventional Agents to Biologics Stephen B. Hanauer, M.D. University of Chicago Treatment Goals Induce and maintain response/ remission Prevent complications Improve quality
More informationReview article: the long-term management of ulcerative colitis
Aliment Pharmacol Ther 2004; 20 (Suppl. 4): 97 101. Review article: the long-term management of ulcerative colitis S. B. HANAUER Section of Gastroenterology, University of Chicago, Chicago, IL, USA SUMMARY
More informationClinical Medicine Insights: Gastroenterology. Once-Daily MMX Mesalamine in the Management of Ulcerative Colitis
Clinical Medicine Insights: Gastroenterology Review Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Once-Daily MMX Mesalamine in the Management of Ulcerative
More informationNovel Formulations and Dosing Strategies for 5-ASA
D e c e m b e r 2 0 0 8 w w w. c l i n i c a l a d v a n c e s. c o m V o l u m e 4, I s s u e 1 2, S u p p l e m e n t 2 8 Novel Formulations and Dosing Strategies for 5-ASA A Summary of Selected Recent
More informationClinical Trials in IBD. Bruce Yacyshyn MD Professor of Medicine Division of Digestive Diseases
Clinical Trials in IBD Bruce Yacyshyn MD Professor of Medicine Division of Digestive Diseases Objectives Today s discussion will address the following topics: Similarities and differences between Crohn
More informationUlcerative colitis (UC) is a chronic relapsing and remitting inflammatory
TREATMENT UPDATE The Efficacy of Oral 5-ASAs in the Treatment of Active Ulcerative Colitis: A Systematic Review Sunanda V. Kane, MD, MSPH,* David J. Bjorkman, MD, MSPH, SM (Epid) *University of Chicago,
More informationModerately to severely active ulcerative colitis
Adalimumab in the Treatment of Moderate-to-Severe Ulcerative Colitis: ULTRA 2 Trial Results Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients
More informationFERRING PHARMACEUTICALS. Enjoy The simple COR/939/2014/CH3
Enjoy The simple pleasures of life COR/939/2014/CH3 Ulcerative colitis disrupts the simple pleasures in life Patients with ulcerative colitis may live with a considerable symptom burden despite medical
More informationArticle: Min, T and Ford, AC (2016) Efficacy of mesalazine in IBS. Gut, 65 (1). pp ISSN
This is a repository copy of Efficacy of mesalazine in IBS. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/97338/ Version: Accepted Version Article: Min, T and Ford, AC (2016)
More informationOral mesalamine formulations are widely used for the
ORIGINAL ARTICLE Direct Comparison of Two Different Mesalamine Formulations for the Induction of Remission in Patients with Ulcerative Colitis: A Double-blind, Randomized Study Hiroaki Ito, MD,* Mitsuo
More informationUntil recently, treatment of active ulcerative colitis
ORIGINAL ARTICLE Prognostic Significance of Endoscopic Remission in Patients with Active Ulcerative Colitis Treated with Oral and Topical Mesalazine: A Prospective, Multicenter Study Gianmichele Meucci,
More informationNew treatment options in UC. Rob Bryant IBD Consultant Royal Adelaide Hospital
New treatment options in UC Rob Bryant IBD Consultant Royal Adelaide Hospital Talk Outline 1. Raising expectations 2. Optimising UC therapy 3. Clinical trials 4. What s new on the PBS? 5. Questions 1.
More informationFull title of guideline: Ulcerative colitis: the management of ulcerative colitis
Economic Plan This document identifies the priorities for economic analysis and the proposed methods for addressing these questions as described in section 7.1.3 of the Guidelines Manual (2009). 1 Guideline
More informationEfficacy of 5-Aminosalicylates in Ulcerative Colitis: Systematic Review and Meta-Analysis
CLINICAL AND SYSTEMATIC S nature publishing group 601 Efficacy of 5-Aminosalicylates in Ulcerative Colitis: Systematic Review and Meta-Analysis Alexander C. Ford, MBChB, MD, MRCP 1, 2, Je an - Pau l Ach
More informationavailable at
Journal of Crohn's and Colitis (2009) 3, 32 37 available at www.sciencedirect.com An economic evaluation comparing once daily with twice daily mesalazine for maintaining remission based on results from
More informationUlcerative Colitis: State of the Art 2006
Ulcerative Colitis: State of the Art David T. Rubin, MD Assistant Professor of Medicine Inflammatory Bowel Disease Center University of Chicago Improving Management of Ulcerative Colitis (UC) Better classification/diagnostic
More informationDoncaster & Bassetlaw Medicines Formulary
Doncaster & Bassetlaw Medicines Formulary Section 1.5 Chronic Bowel Disorders (including IBD) Aminosalicylates: Mesalazine 400mg and 800mg MR Tablets (Octasa) Mesalazine 1.2g MR Tablets (Mezavant XL) Mesalazine
More information5-ASA for the treatment of Crohn s disease DR. STEPHEN HANAUER FEINBERG SCHOOL OF MEDICINE, NORTHWESTERN UNIVERSITY, CHICAGO, IL, USA
5-ASA for the treatment of Crohn s disease DR. STEPHEN HANAUER FEINBERG SCHOOL OF MEDICINE, NORTHWESTERN UNIVERSITY, CHICAGO, IL, USA Background RCTs investigating the efficacy of aminosalicylates for
More informationAmerican Gastroenterological Association Technical Review on the Management of Mild to Moderate Ulcerative Colitis
1 American Gastroenterological Association Technical Review on the Management of Mild to Moderate Ulcerative Colitis Siddharth Singh, MD, MS 1 *; Joseph D. Feuerstein, MD 2 *; David G. Binion, MD 3 ; William
More informationUlcerative Colitis: Refining our Management and Incorporating Newer Concepts
Ulcerative Colitis: Refining our Management and Incorporating Newer Concepts Asher Kornbluth, MD Clinical Professor of Medicine The Henry D. Janowitz The Mt. Sinai School of Medicine Refining our Management
More informationTitle: Authors: Journal:
IMPORTANT COPYRIGHT NOTICE: This electronic article is provided to you by courtesy of Ferring Pharmaceuticals. The document is provided for personal usage only. Further reproduction and/or distribution
More informationClinical Study Clinical Study of the Relation between Mucosal Healing and Long-Term Outcomes in Ulcerative Colitis
Hindawi Publishing Corporation Gastroenterology Research and Practice Volume 2013, Article ID 192794, 6 pages http://dx.doi.org/10.1155/2013/192794 Clinical Study Clinical Study of the Relation between
More informationEndpoints for Stopping Treatment in UC
Endpoints for Stopping Treatment in UC Jana G. Hashash, MD Assistant Professor of Medicine Inflammatory Bowel Disease Center Division of Gastroenterology, Hepatology, and Nutrition University of Pittsburgh
More informationSynopsis. Clinical Report Synopsis for Protocol Name of Company: Otsuka Pharmaceutical Development & Commercialization, Inc.
Synopsis Clinical Report Synopsis for Protocol 197-02-220 Name of Company: Otsuka Pharmaceutical Development & Commercialization, Inc. Name of Product: Tetomilast (OPC-6535) Study Title: A Phase 3, Multicenter,
More informationTopical therapy is underused in patients with ulcerative colitis
Journal of Crohn's and Colitis (2014) 8, 56 63 Available online at www.sciencedirect.com ScienceDirect Topical therapy is underused in patients with ulcerative colitis F. Seibold a, f,, N. Fournier b,
More informationAzathioprine for Induction and Maintenance of Remission in Crohn s Disease
Azathioprine for Induction and Maintenance of Remission in Crohn s Disease William J. Sandborn, MD Chief, Division of Gastroenterology Director, UCSD IBD Center Objectives Azathioprine as induction and
More informationClinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis a 6-month placebo-controlled trial
Alimentary Pharmacology and Therapeutics Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis a 6-month placebo-controlled trial G. R. Lichtenstein*, G. L.
More informationCCFA. Crohns Disease vs UC: What is the best treatment for me? November
CCFA Crohns Disease vs UC: What is the best treatment for me? November 8 2009 Ellen J. Scherl,, MD, FACP,AGAF Roberts Inflammatory Bowel Disease Center Weill Medical College Cornell University New York
More informationHow do I choose amongst medicines for inflammatory bowel disease. Maria T. Abreu, MD
How do I choose amongst medicines for inflammatory bowel disease Maria T. Abreu, MD Overview of IBD Pathogenesis Bacterial Products Moderately Acutely Inflamed Chronic Inflammation = IBD Normal Gut Mildly
More informationRelease of 5-Aminosalicylic Acid (5-ASA) from Mesalamine Formulations at Various ph Levels
Adv Ther (2015) 32:477 484 DOI 10.1007/s12325-015-0206-4 ORIGINAL RESEARCH Release of 5-Aminosalicylic Acid (5-ASA) from Mesalamine Formulations at Various ph Levels Adeyinka Abinusawa. Srini Tenjarla
More informationOld and new steroids: hitting the target
Oxford Inflammatory Bowel Disease & Hepatology MasterClass Old and new steroids: hitting the target Silvio Danese, MD, PhD IBD Center Division of Gastroenterology Istituto Clinico Humanitas, Milan, Italy
More informationOxford Inflammatory Bowel Disease MasterClass The mesalazine chamaeleon
Oxford Inflammatory Bowel Disease MasterClass The mesalazine chamaeleon Ailsa Hart Lead IBD Unit, St Mark s Hospital Senior Clinical lecturer Imperial College, London Oxford Inflammatory Bowel Disease
More informationTop Clinical Tips for Inflammatory Bowel Disease
Job bag number: UK/AS/0165/07-13 Date of preparation: July 2013 Top Clinical Tips for Inflammatory Bowel Disease Dr Ayesha Akbar Consultant Gastroenterologist Honorary Senior Lecturer Contents-focus on
More informationMedical Management of Inflammatory Bowel Disease
Medical Management of Inflammatory Bowel Disease John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University John K. Marshall: Conflicts of Interest Speaker: AbbVie, Allergan, Ferring,
More informationCLINICAL TRIAL PROTOCOL
CLINICAL TRIAL PROTOCOL Protocol Title: A randomised, open study of aminosalicylate withdrawal in patients with ulcerative colitis in established remission on combination treatment of azathioprine (or
More informationNational Institute for Health and Care Excellence
National Institute for Health and Care Excellence 4-year surveillance (2017) Ulcerative colitis: management (2013) NICE guideline CG166 Appendix A.2: Summary of new evidence from surveillance Patient information
More informationMucosal healing: does it really matter?
Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does it really matter? Professor Jean-Frédéric Colombel, New York, USA Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does
More informationTitle: Author: Journal:
IMPORTANT COPYRIGHT NOTICE: This electronic article is provided to you by courtesy of Ferring Pharmaceuticals. The document is provided for personal usage only. Further reproduction and/or distribution
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Associate Professor of Clinical Pediatrics Division of Gastroenterology,
More informationTreating to Achieve a Target and Disease Monitoring in 2015: State of the Art
Treating to Achieve a Target and Disease Monitoring in 2015: State of the Art David T. Rubin, MD The Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology and Nutrition
More informationUlcerative Colitis: Experience at a Tertiary Care Center
Original Article Ulcerative Colitis: Experience at a Tertiary Care Center Nasir Khokhar From Division of gastroenterology, Department of Medicine, Shifa International Hospital and Shifa College of Medicine,
More informationTo help protect your privacy, PowerPoint prevented this external picture from being automatically downloaded. To download and display this picture,
To help protect your privacy, PowerPoint prevented this external picture from being automatically downloaded. To download and display this picture, click Options in the Message Bar, and then click Enable
More informationUpdate on Biologics in Ulcerative Colitis. Scott Plevy, MD University of North Carolina Chapel Hill, NC
Update on Biologics in Ulcerative Colitis Scott Plevy, MD University of North Carolina Chapel Hill, NC Objectives Discuss the latest advances in the pharmacologic management of ulcerative colitis Describe
More informationCrohn's disease. Appendix J. Clinical Guideline < > 10 October Review of Cochrane ASA review
Crohn's disease Clinical Guideline < > Review of Cochrane ASA review 0 October 202 Commissioned by the National Institute for Health and Clinical Excellence Review of Cochrane 5-ASA review Contents Published
More informationClinical Policy: Budesonide (Uceris) Reference Number: CP.PCH.11 Effective Date: Last Review Date: Line of Business: Commercial, HIM*
Clinical Policy: (Uceris) Reference Number: CP.PCH.11 Effective Date: 08.14.18 Last Review Date: 11.18 Line of Business: Commercial, HIM* Revision Log See Important Reminder at the end of this policy for
More informationAn Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease. David A. Schwartz, MD
An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University
More informationImplementation of disease and safety predictors during disease management in UC
Implementation of disease and safety predictors during disease management in UC DR ARIELLA SHITRIT DIGESTIVE DISEASES INSTITUTE SHAARE ZEDEK MEDICAL CENTER JERUSALEM Case presentation A 52 year old male
More informationPositioning Biologics in Ulcerative Colitis
Positioning Biologics in Ulcerative Colitis Bruce E. Sands, MD, MS Acting Chief, Gastrointestinal Unit Massachusetts General Hospital Associate Professor of Medicine Harvard Medical School Sequential Therapies
More informationThe quantitative validation of non-endoscopic disease activity indices in ulcerative colitis
Alimentary Pharmacology & Therapeutics The quantitative validation of non-endoscopic disease activity indices in ulcerative colitis P. D. R. HIGGINS*, J. LEUNG, M.SCHWARTZà, J.MAPILI,P.A.WREN &E.M.ZIMMERMANN*
More informationDefinitions. Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency)
CROHN S DISEASE Definitions Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency) Recurrence: The reappearance of lesions after surgical resection Endoscopic remission:
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Assistant Professor of Clinical Pediatrics Division of Gastroenterology,
More informationPosition of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy
Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy Stephen B. Hanauer, MD University of Chicago Potential Conflicts: Centocor/Schering, Abbott, UCB, Elan, Berlex, PDL Goals of Treatment
More informationIBD Updates. Themes in IBD IBD management journey. New tools for therapeutic monitoring. First-line treatment in IBD
IBD Updates Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida Themes in IBD 213 First-line treatment in IBD New tools for therapeutic monitoring Biologic therapy for CD and
More informationENTYVIO (VEDOLIZUMAB)
ENTYVIO (VEDOLIZUMAB) UnitedHealthcare Community Plan Medical Benefit Drug Policy Policy Number: CS2017D0053F Effective Date: July 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationNON INVASIVE MONITORING OF MUCOSAL HEALING IN IBD. THE ROLE OF BOWEL ULTRASOUND. Fabrizio Parente
NON INVASIVE MONITORING OF MUCOSAL HEALING IN IBD. THE ROLE OF BOWEL ULTRASOUND Fabrizio Parente Gastrointestinal Unit, A.Manzoni Hospital, Lecco & L.Sacco School of Medicine,University of Milan - Italy
More informationPublic Assessment Report Scientific discussion. Mesalazin ESPL (mesalazine) SE/H/1654/01/DC
Public Assessment Report Scientific discussion Mesalazin ESPL (mesalazine) SE/H/1654/01/DC This module reflects the scientific discussion for the approval of Mesalazin ESPL. The procedure was finalised
More informationΑναφορές εκβάσεων από τους ασθενείς (Patient Reported Outcomes): Μπορούν να αναβαθμίσουν τον τρόπο παρακολούθησης της νόσου; Γιώργος Μπάμιας
Αναφορές εκβάσεων από τους ασθενείς (Patient Reported Outcomes): Μπορούν να αναβαθμίσουν τον τρόπο παρακολούθησης της νόσου; Γιώργος Μπάμιας Σύγκρουση συμφερόντων Γιώργος Μπάμιας τιμητικές αμοιβές απο
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationTreatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort
Alimentary Pharmacology and Therapeutics Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort N. Gies, K. I. Kroeker, K. Wong & R. N. Fedorak Division
More informationENTYVIO (VEDOLIZUMAB)
ENTYVIO (VEDOLIZUMAB) UnitedHealthcare Commercial Medical Benefit Drug Policy Policy Number: 2017D0053F Effective Date: July 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationUlcerative colitis (UC) is a chronic inflammatory
Induction and Maintenance Therapy with Vedolizumab, a Novel Biologic Therapy for Ulcerative Colitis Feagan BG, Rutgeerts P, Sands BE, et al; GEMINI 1 Study Group. Vedolizumab as induction and maintenance
More informationA Review of Delayed-Release MMX Mesalamine: It s Use in the Treatment of Ulcerative Colitis
A Review of Delayed-Release MMX Mesalamine: It s Use in the Treatment of Ulcerative Colitis Reem Sharaiha 1 and Arun Swaminath 2 REVIEW 1 Fellow, Division of Digestive and Liver Diseases, Columbia University
More informationORIGINAL ARTICLE. Abstract. Introduction
ORIGINAL ARTICLE Annals of Gastroenterology (2014) 27, 1-5 Effectiveness of adalimumab for ambulatory ulcerative colitis patients after failure of infliximab treatment: a first real-life experience in
More informationTreatment Guidelines and Clinical Practice: Optimizing Foundational Therapies for Ulcerative Colitis
O c t o b e r 2 0 0 8 w w w. c l i n i c a l a d v a n c e s. c o m V o l u m e 4, I s s u e 1 0, S u p p l e m e n t 2 2 Faculty Stephen B. Hanauer, MD Program Chair Professor of Medicine and Clinical
More informationEvaluation of the severity of ulcerative colitis using endoscopic dual red imaging targeting deep vessels
Evaluation of the severity of ulcerative colitis using endoscopic dual red imaging targeting deep vessels Authors Makoto Naganuma 1, 2, Naohisa Yahagi 3,RiekoBessho 1, Keiko Ohno 1, Mari Arai 1, Makoto
More informationEmerging Therapies in IBD 2006
Overview Emerging Therapies in IBD 26 David T. Rubin, MD Assistant Professor of Medicine Inflammatory Bowel Disease Center University of Chicago Describe the unmet needs of therapy in IBD Emerging biologic
More informationClinical Medicine Reviews in Therapeutics. Pharmacotherapy of Ulcerative Colitis: What Role for Mesalamine?
Clinical Medicine Reviews in Therapeutics R e v i e w Pharmacotherapy of Ulcerative Colitis: What Role for Mesalamine? Adam Harris 1, Mitul Patel 1 and Samir A. Shah 2 1 Warren Alpert School of Medicine
More informationStudy on Follow-Up of Ulcerative Colitis Patients on Sulfasalazine At Our Hospital Retrospectivecohort Study.
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 17, Issue 9 Ver. 10 (September. 2018), PP 40-46 www.iosrjournals.org Study on Follow-Up of Ulcerative
More informationUlcerative colitis (UC) is a relatively common inflammatory
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2012;10:513 519 Efficacy of Topical 5-Aminosalicylates in Preventing Relapse of Quiescent Ulcerative Colitis: A Meta-analysis ALEXANDER C. FORD,*, KHURRAM J. KHAN,
More informationENTYVIO (VEDOLIZUMAB)
ENTYVIO (VEDOLIZUMAB) UnitedHealthcare Oxford Clinical Policy Policy Number: PHARMACY 285.8 T2 Effective Date: November 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 CONDITIONS OF COVERAGE...
More informationDr. Elmer Schabel, MD. Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany (No conflicts of interest)
EMA workshop on the development of new medicinal products for the treatment of ulcerative colitis and Crohn s disease Overview of authorised medicines for IBD in Europe - previous regulatory positions
More informationLatest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals
Latest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals Stephen Hanauer, MD Professor of Medicine Medical Director, Digestive Disease Center Northwestern Medicine Chicago, Illinois Speaker
More informationIBD Case Studies. David Rowbotham. Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology & Hepatology Auckland City Hospital
IBD Case Studies David Rowbotham Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology & Hepatology Auckland City Hospital Dr David Rowbotham The Leeds Teaching Hospitals NHS Trust
More informationDoes Fecal Microbiota Transplantation Cause Clinical Remission in Patients with Ulcerative Colitis?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 12-2017 Does Fecal Microbiota Transplantation
More informationINFLAMMATORY BOWEL DISEASE
1. Medical Condition INFLAMMATORY BOWEL DISEASE (IBD) specifically includes Crohn s disease (CD) and ulcerative colitis (UC) but also includes IBD unclassified (IBDu), seen in about 10% of cases. These
More informationEmerging g therapies for IBD: A practical approach to positioning. Sequential Therapies for IBD
Emerging g therapies for IBD: A practical approach to positioning Stephen B. Hanauer, MD Sequential Therapies for IBD Disease Severity at Presentation Severe Anti-TNF +/IS Cyclosporine (UC) Colectomy (UC)
More informationMedical Therapy for Pediatric IBD: Efficacy and Safety
Medical Therapy for Pediatric IBD: Efficacy and Safety Betsy Maxwell, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Pediatric IBD: Defining Remission
More informationGionata Fiorino VEDOLIZUMAB E IBD. Un nuovo target terapeutico
Gionata Fiorino VEDOLIZUMAB E IBD Un nuovo target terapeutico Anti cell adhesion molecules Danese S, NEJM 2011 6 Steps leukocyte recruitment Fiorino G. et al. 2010 Vedolizumab Blocks Fewer Biological Pathways
More informationLong-term outcome after infliximab for refractory ulcerative colitis
Journal of Crohn's and Colitis (2008) 2, 219 225 available at www.sciencedirect.com Long-term outcome after infliximab for refractory ulcerative colitis Marc Ferrante a, Séverine Vermeire a, Herma Fidder
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 October 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 October 2012 REMICADE 100 mg, powder for concentrate for solution for infusion B/1 vial (CIP code: 562 070-1) Applicant:
More informationSER-287 Phase 1b topline study results in patients with mild-to-moderate Ulcerative Colitis October 2, 2017
SER-287 Phase 1b topline study results in patients with mild-to-moderate Ulcerative Colitis October 2, 2017 Leading the Microbiome Revolution Forward Looking Statements Some of the statements in this presentation
More informationReview article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease
Aliment Pharmacol Ther 23; 18 (Suppl. 2): 1 5. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease P. MUNKHOLM Department of Medical Gastroenterology, Hvidovre
More informationPrimary & Secondary Care Inflammatory Bowel Disease Pathway February 2018
South East London Area Prescribing Committee: Primary & Secondary Care Inflammatory Bowel Disease Pathway February 2018 Developed by: South East London IBD Pathway Development Group Approved: February
More informationSeptember 12, 2015 Millie D. Long MD, MPH, FACG
Update on Biologic Therapy in 2015 September 12, 2015 Millie D. Long MD, MPH, FACG Assistant Professor of Medicine Inflammatory Bowel Disease Center University of North Carolina-Chapel Hill Outline Crohn
More informationRandomised clinical trial: once- vs. twice-daily prolongedrelease mesalazine for active ulcerative colitis
Alimentary Pharmacology and Therapeutics Randomised clinical trial: once- vs. twice-daily prolongedrelease mesalazine for active ulcerative colitis B. Flourie*, H. Hagege, G. Tucat, D. Maetz,X.Hebuterne,
More informationReview article: remission rates achievable by current therapies for inflammatory bowel disease
Alimentary Pharmacology and Therapeutics Review article: remission rates achievable by current therapies for inflammatory bowel disease L. Peyrin-Biroulet* & M. Lémann,1 *Inserm U954 and Department of
More informationMaintenance therapy for ulcerative colitis has no impact on changes in the extent of ulcerative colitis
Journal of Crohn s and Colitis (2007) 1, 21 27 available at www.sciencedirect.com Maintenance therapy for ulcerative colitis has no impact on changes in the extent of ulcerative colitis N. Eleftheriadis
More information